RxDoctor Payments Data

Ali Sovari, MD

Clinical Cardiac Electrophysiology · Oxnard, CANPI 1184823494

Payments from drug & device makers

$65,495in general payments, 2019–2025

Across 549 payments — averaging $119.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$21K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$17K
  • Medtronic$14K
  • Abbott$8K
  • Biosense Webster, Inc.$1K
  • Cardiva Medical, Inc.$557
  • plus $3K from 27 others

What the payments were for

  • Consulting fees$2,6575%
  • Speaking & faculty fees$20,75037%
  • Travel & lodging$12,45622%
  • Food & beverage$19,62435%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$65,495 in reported general payments places this provider in the 60th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$1,133,950
Medicare patients
972
Services billed
7,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban268$217,186
XareltoRivaroxaban53$48,943
EntrestoSacubitril/Valsartan52$45,015
JardianceEmpagliflozin11$14,628
BrilintaTicagrelor13$7,138
Amiodarone Hcl127$4,109
Flecainide Acetate109$3,622
Metoprolol Succinate159$1,854
Atorvastatin Calcium61$712
ClopidogrelClopidogrel Bisulfate64$528
Carvedilol83$514
Hydralazine Hcl54$389
Amlodipine Besylate86$341
Digoxin14$272
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$97$217,186268 claims
Johnson & JohnsonXarelto$37$48,94353 claims
NovartisEntresto$299$45,01552 claims
Boehringer IngelheimJardiance$18$14,62811 claims
AstraZenecaBrilinta$124$7,13813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Oxnard

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →